Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetyl hexapeptide-3 is a synthetic peptide, also known as Argireline, primarily used as an anti-wrinkle ingredient in cosmetic products. It is a fragment of SNAP25 (synaptosome-associated protein 25), which is involved in the SNARE complex responsible for synaptic vesicle exocytosis and neurotransmitter release. By acting as a competitive inhibitor of SNAP25, acetyl hexapeptide-3 inhibits the formation of the SNARE complex, thereby reducing acetylcholine exocytosis at neuromuscular synapses. This mechanism leads to reduced muscle contraction and relaxation of facial muscles, mimicking some effects of botulinum toxin (Botox) but via topical application. The compound has been investigated for its ability to reduce facial wrinkles and improve skin appearance[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acetyl hexapeptide-3.